SeaStar Medical Holding Corp (ICU) Form 10-Q — Aug 12, 2026
SeaStar Medical's Q2 2026 10-Q carries an explicit going-concern warning: with $7.0 million in cash and a $7.3 million net loss over the first six months of 2026, management states cash on hand is not sufficient to fund operations for at least 12 months, raising substantial doubt about the company's ability to continue as a going concern. Operationally, QUELIMMUNE sales are growing, with Q2 net revenue up 82% year over year to $615 thousand and six-month revenue of $1.1 million, but the Q2 net loss widened 86% to $3.7 million as R&D spending jumped 143% to $2.5 million to fund the NEUTRALIZE-AKI adult pivotal trial, with topline results anticipated in 2027.
Key figures
- Revenue
- 1110000
- Total Debt
- 134000
- Revenue Yoy
- +76% six months ended June 30, 2026
- Total Assets
- 8649000
- Cash Position
- 6959000
- Shares Outstanding
- 4406841
- Employees
- 18
- Cash Dec31 2025
- 11980000
- Revenue Q2 2026
- 615000
- Shelf Remaining
- 55900000
- Rd Expense Q2 2026
- 2520000
- Sepa Total Capacity
- 15000000
- Accumulated Deficit
- 158965000
- Rd Expense Q2 growth
- +143%
- Revenue Q2 growth yoy
- +82%
- Sepa Capacity Remaining
- 13800000
- Total Stockholders Equity
- 4296000
- Atm Proceeds Since Inception
- 10400000
- Cumulative Quelimmune Revenue
- 2500000
- Stockholders Equity Dec31 2025
- 10416000
Price after filing
Close on the filing date to close N calendar days later (from $3.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.